Dublin Core
Title
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy
Subject
Polypharmacy
Description
Polypharmacy is a necessary and important aspect of drug treatment; however, it
becomes a challenge when the medication risks outweigh the benefits for an individual
patient. Drug–drug interactions and the introduction of prescribing cascades are
common features of polypharmacy, which can lead to ineffectiveness and increased risk
of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drugrelated biomarkers have attracted considerable attention as targets for pharmacogenetic
(PGx) testing due to their impact on drug metabolism and response. This Special Issue is
devoted to explore the status and initiatives taken to circumvent ineffectiveness and to
improve medication safety for polypharmacy patients. Specific areas include drug–drug
interactions and consequences thereof in therapeutic management, including PK- and
PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene
and drug–drug gene interactions; medication reviews; development and application of
deprescribing tools; and drivers and barriers to overcome for successful implementation
in the healthcare system
becomes a challenge when the medication risks outweigh the benefits for an individual
patient. Drug–drug interactions and the introduction of prescribing cascades are
common features of polypharmacy, which can lead to ineffectiveness and increased risk
of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drugrelated biomarkers have attracted considerable attention as targets for pharmacogenetic
(PGx) testing due to their impact on drug metabolism and response. This Special Issue is
devoted to explore the status and initiatives taken to circumvent ineffectiveness and to
improve medication safety for polypharmacy patients. Specific areas include drug–drug
interactions and consequences thereof in therapeutic management, including PK- and
PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene
and drug–drug gene interactions; medication reviews; development and application of
deprescribing tools; and drivers and barriers to overcome for successful implementation
in the healthcare system
Creator
Charlotte Vermehren
Niels Westergaard
Niels Westergaard
Source
https://www.mdpi.com/books/pdfdownload/book/6018
Publisher
MDPI
St. Alban-Anlage 66
4052 Basel, Switzerland
St. Alban-Anlage 66
4052 Basel, Switzerland
Date
2022
Contributor
J®F
Rights
Creative Commons
license CC BY-NC-ND
license CC BY-NC-ND
Format
Pdf
Language
English
Type
Textbooks
Identifier
https://doi.org/10.3390/books978-3-0365-5161-6
ISBN 978-3-0365-5162-3 (Hbk); ISBN 978-3-0365-5161-6 (PDF)
ISBN 978-3-0365-5162-3 (Hbk); ISBN 978-3-0365-5161-6 (PDF)